Amberstone Biosciences
- Founded: 2018
- Location: Laguna Hills, CA
- Employee range: 11 - 50
- Clinical stage: Clin0
- Therapy area: Oncology
- Drug types: ONC
- Lead product: ABS-101
- Product link: https://amberstonebio.com/technology/
- Funding: $12M A Jan 2022
amberstonebio.com linkedin.com job board
Short description:
Solid Tumor Therapies
Drug notes:
ABS-102 RD oncology; ABS-110 RD oncology; ABS-280 RD oncology
Long description:
Amberstone Biosciences aims to create safe and effective immunotherapies. Their T-MATE: Tumor Microenvironment Activated Therapeutics pipeline is made of therapeutic antibodies that target tumors with less off-target damage. Amberstone utilizes their discovery platform, AmberFlow, a high-throughput method to identify novel therapeutic targets via proprietary single-cell microfluidics. AmberFlow’s technology can evaluate candidates quickly, producing high-content information without limitations of molecular format, cell source, or target. Amberstone’s pipeline strategy can target various tumor types and autoimmune diseases.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com